| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.564 | 0.013 | 0.596 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.596 0.007 CID_19113 | CID_19113 | |
| 0.524 | 0.005 | 0.524 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.132 0.09 CID_19113 | ||
| 0.507 | 0.005 | 0.507 | Protein kinase (CK1) gamma 1 inhibitor | 0.247 0.029 CID_19113 | ||
| 0.452 | 0.005 | 0.452 | Protein kinase (CK1) gamma 3 inhibitor | 0.207 0.043 CID_19113 | ||
| 0.452 | 0.01 | 0.452 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.172 0.076 CID_19113 | ||
| 0.477 | 0.036 | 0.477 | Cholesterol antagonist | 0.376 0.055 CID_19113 | ||
| 0.438 | 0.008 | 0.438 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.234 0.054 CID_19113 | ||
| 0.416 | 0.006 | 0.416 | Protein kinase (CK1) gamma inhibitor | 0.2 0.044 CID_19113 | ||
| 0.437 | 0.043 | 0.569 | Angiogenesis inhibitor | 0.569 0.02 CID_19113 | CID_19113 | |
| 0.377 | 0.007 | 0.377 | MAP-kinase-activated kinase 5 inhibitor | 0.182 0.129 CID_19113 | ||
| 0.385 | 0.017 | 0.409 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.409 0.013 CID_19113 | CID_19113 | |
| 0.344 | 0.011 | 0.344 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.247 0.032 CID_19113 | ||
| 0.358 | 0.027 | 0.362 | Peroxidase inhibitor | 0.362 0.026 CID_19113 | CID_19113 | |
| 0.337 | 0.007 | 0.337 | Protein kinase (CK1) gamma 2 inhibitor | 0.174 0.04 CID_19113 | ||
| 0.339 | 0.013 | 0.352 | Gastrin inhibitor | 0.352 0.01 CID_19113 | CID_19113 | |
| 0.339 | 0.014 | 0.339 | Vascular endothelial growth factor 3 antagonist | 0.289 0.02 CID_19113 | ||
| 0.325 | 0.007 | 0.325 | Polo-like kinase-3 inhibitor | 0.249 0.024 CID_19113 | ||
| 0.347 | 0.029 | 0.347 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.23 0.063 CID_19113 | ||
| 0.327 | 0.01 | 0.327 | Growth factor agonist | 0.202 0.06 CID_19113 | ||
| 0.337 | 0.023 | 0.337 | CDC-like kinase 2 inhibitor | 0.229 0.053 CID_19113 | ||
| 0.379 | 0.071 | 0.392 | GABA C receptor rho-3 antagonist | 0.392 0.065 CID_19113 | CID_19113 | |
| 0.332 | 0.028 | 0.332 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.291 0.039 CID_19113 | ||
| 0.316 | 0.02 | 0.421 | Vascular endothelial growth factor antagonist | 0.421 0.012 CID_19113 | CID_19113 | |
| 0.31 | 0.015 | 0.31 | Neuropeptide Y2 antagonist | 0.282 0.029 CID_19113 | ||
| 0.311 | 0.019 | 0.423 | Vascular endothelial growth factor 2 antagonist | 0.423 0.011 CID_19113 | CID_19113 | |
| 0.312 | 0.022 | 0.312 | Protein kinase C nu inhibitor | 0.161 0.064 CID_19113 | ||
| 0.3 | 0.011 | 0.3 | Vascular endothelial growth factor 1 antagonist | 0.156 0.039 CID_19113 | ||
| 0.303 | 0.028 | 0.303 | 5 Hydroxytryptamine 1E antagonist | 0.291 0.035 CID_19113 | ||
| 0.368 | 0.1 | 0.368 | 5 Hydroxytryptamine release inhibitor | 0.364 0.103 CID_19113 | ||
| 0.301 | 0.033 | 0.301 | Anesthetic general | 0.283 0.038 CID_19113 | ||
| 0.267 | 0.005 | 0.267 | Stem cell growth factor agonist | 0.135 0.024 CID_19113 | ||
| 0.265 | 0.005 | 0.294 | 5 Hydroxytryptamine 3A agonist | 0.294 0.004 CID_19113 | CID_19113 | |
| 0.302 | 0.043 | 0.302 | DNA synthesis inhibitor | 0.23 0.083 CID_19113 | ||
| 0.289 | 0.039 | 0.321 | MAP kinase kinase 2 inhibitor | 0.321 0.028 CID_19113 | CID_19113 | |
| 0.258 | 0.015 | 0.258 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | 0.251 0.016 CID_19113 | ||
| 0.251 | 0.013 | 0.293 | ATPase inhibitor | 0.293 0.007 CID_19113 | CID_19113 | |
| 0.242 | 0.004 | 0.242 | Acetyl-CoA transferase inhibitor | 0.14 0.006 CID_19113 | ||
| 0.241 | 0.005 | 0.241 | Interleukin 2 antagonist | 0.146 0.02 CID_19113 | ||
| 0.243 | 0.007 | 0.243 | Raf kinase C inhibitor | 0.221 0.008 CID_19113 | ||
| 0.231 | 0.004 | 0.231 | NMDA receptor agonist | 0.196 0.005 CID_19113 | ||
| 0.23 | 0.016 | 0.23 | Ferrochelatase inhibitor | 0.203 0.022 CID_19113 | ||
| 0.22 | 0.01 | 0.226 | EphA2 antagonist | 0.226 0.009 CID_19113 | CID_19113 | |
| 0.217 | 0.009 | 0.254 | Interleukin 8 antagonist | 0.254 0.005 CID_19113 | CID_19113 | |
| 0.21 | 0.003 | 0.21 | NMDA receptor glycine site agonist | 0.162 0.004 CID_19113 | ||
| 0.245 | 0.041 | 0.33 | LIM domain kinase 1 inhibitor | 0.33 0.015 CID_19113 | CID_19113 | |
| 0.32 | 0.117 | 0.32 | MAP kinase kinase 6 inhibitor | 0.243 0.2 CID_19113 | ||
| 0.25 | 0.048 | 0.25 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.198 0.067 CID_19113 | ||
| 0.228 | 0.029 | 0.228 | 5 Hydroxytryptamine 3E antagonist | 0.227 0.03 CID_19113 | ||
| 0.223 | 0.027 | 0.301 | M18 aspartyl aminopeptidase inhibitor | 0.301 0.012 CID_19113 | CID_19113 | |
| 0.242 | 0.049 | 0.242 | CDC-like kinase 4 inhibitor | 0.126 0.122 CID_19113 | ||
| 0.247 | 0.059 | 0.254 | EphB2 antagonist | 0.254 0.054 CID_19113 | CID_19113 | |
| 0.254 | 0.077 | 0.254 | Aryl hydrocarbon receptor agonist | 0.213 0.095 CID_19113 | ||
| 0.191 | 0.016 | 0.191 | TIE antagonist | 0.165 0.02 CID_19113 | ||
| 0.195 | 0.021 | 0.195 | Aurora-C kinase inhibitor | 0.148 0.053 CID_19113 | ||
| 0.193 | 0.02 | 0.237 | Chemokine receptor antagonist | 0.237 0.013 CID_19113 | CID_19113 | |
| 0.193 | 0.022 | 0.232 | Neuropeptide Y1 antagonist | 0.232 0.011 CID_19113 | CID_19113 | |
| 0.252 | 0.081 | 0.252 | Aldehyde oxidase inhibitor | 0.155 0.134 CID_19113 | ||
| 0.196 | 0.025 | 0.196 | Ephrin antagonist | 0.196 0.025 CID_19113 | ||
| 0.208 | 0.039 | 0.208 | Phospholipase C inhibitor | 0.192 0.05 CID_19113 | ||
| 0.181 | 0.017 | 0.181 | TIE-2 antagonist | 0.142 0.023 CID_19113 | ||
| 0.167 | 0.004 | 0.167 | Acetyl-CoA transferase 1 inhibitor | 0.083 0.005 CID_19113 | ||
| 0.18 | 0.021 | 0.18 | Platelet activating factor alpha antagonist | 0.179 0.021 CID_19113 | ||
| 0.195 | 0.038 | 0.195 | MAP kinase kinase 5 inhibitor | 0.19 0.046 CID_19113 | ||
| 0.173 | 0.019 | 0.197 | Sphingosine 1-phosphate receptor 2 antagonist | 0.197 0.008 CID_19113 | CID_19113 | |
| 0.181 | 0.033 | 0.181 | Epidermal growth factor receptor kinase inhibitor | 0.145 0.051 CID_19113 | ||
| 0.164 | 0.017 | 0.177 | Urease inhibitor | 0.177 0.014 CID_19113 | CID_19113 | |
| 0.197 | 0.051 | 0.197 | Succinate dehydrogenase inhibitor | 0.196 0.052 CID_19113 | ||
| 0.156 | 0.014 | 0.156 | MAP kinase kinase 1 inhibitor | 0.144 0.019 CID_19113 | ||
| 0.173 | 0.031 | 0.173 | Protein kinase (CK2) alpha inhibitor | 0.09 0.087 CID_19113 | ||
| 0.186 | 0.046 | 0.195 | Cyclin-dependent kinase 8 inhibitor | 0.195 0.039 CID_19113 | CID_19113 | |
| 0.166 | 0.027 | 0.166 | Protein kinase (CK2) inhibitor | 0.084 0.079 CID_19113 | ||
| 0.171 | 0.033 | 0.171 | Cystathionine beta-synthase inhibitor | 0.155 0.038 CID_19113 | ||
| 0.17 | 0.036 | 0.17 | TRKB antagonist | 0.124 0.068 CID_19113 | ||
| 0.152 | 0.019 | 0.153 | Electrolyte absorption antagonist | 0.153 0.018 CID_19113 | CID_19113 | |
| 0.273 | 0.139 | 0.341 | Histamine release inhibitor | 0.341 0.104 CID_19113 | CID_19113 | |
| 0.148 | 0.017 | 0.148 | Protein kinase B gamma inhibitor | 0.081 0.045 CID_19113 | ||
| 0.237 | 0.109 | 0.237 | Insulysin inhibitor | 0.21 0.142 CID_19113 | ||
| 0.136 | 0.008 | 0.154 | D-Ala-D-Ala ligase inhibitor | 0.154 0.005 CID_19113 | CID_19113 | |
| 0.167 | 0.039 | 0.167 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.164 0.041 CID_19113 | ||
| 0.167 | 0.039 | 0.167 | Abl kinase inhibitor | 0.163 0.041 CID_19113 | ||
| 0.229 | 0.105 | 0.23 | 5 Hydroxytryptamine uptake stimulant | 0.23 0.103 CID_19113 | CID_19113 | |
| 0.156 | 0.032 | 0.156 | Polo-like kinase-4 inhibitor | |||
| 0.145 | 0.023 | 0.145 | Neuropeptide Y antagonist | 0.14 0.024 CID_19113 | ||
| 0.209 | 0.087 | 0.209 | RNA-directed DNA polymerase inhibitor | 0.188 0.119 CID_19113 | ||
| 0.178 | 0.055 | 0.178 | Catenin beta inhibitor | |||
| 0.177 | 0.056 | 0.177 | Diuretic | 0.121 0.104 CID_19113 | ||
| 0.14 | 0.018 | 0.14 | Histamine N-methyltransferase inhibitor | 0.122 0.029 CID_19113 | ||
| 0.122 | 0.005 | 0.156 | Kainate receptor antagonist | 0.156 0.004 CID_19113 | CID_19113 | |
| 0.146 | 0.029 | 0.219 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.219 0.015 CID_19113 | CID_19113 | |
| 0.202 | 0.086 | 0.219 | Nitric-oxide synthase stimulant | 0.219 0.062 CID_19113 | CID_19113 | |
| 0.118 | 0.004 | 0.118 | Antiviral (Hepatitis D) | 0.078 0.009 CID_19113 | ||
| 0.199 | 0.09 | 0.199 | ErbB-1 antagonist | 0.178 0.119 CID_19113 | ||
| 0.117 | 0.009 | 0.117 | Dopamine D2 agonist | |||
| 0.13 | 0.022 | 0.139 | I kappa B kinase inhibitor | 0.139 0.019 CID_19113 | CID_19113 | |
| 0.164 | 0.057 | 0.164 | Glycogen synthase kinase-3 alpha inhibitor | 0.115 0.088 CID_19113 | ||
| 0.117 | 0.01 | 0.235 | Phosphorylase inhibitor | 0.235 0.004 CID_19113 | CID_19113 | |
| 0.163 | 0.057 | 0.166 | Tyrosine-protein kinase receptor antagonist | 0.166 0.056 CID_19113 | CID_19113 | |
| 0.16 | 0.054 | 0.183 | MAP kinase 3 inhibitor | 0.183 0.032 CID_19113 | CID_19113 | |
| 0.122 | 0.017 | 0.186 | Epoxide hydrolase inhibitor | 0.186 0.008 CID_19113 | CID_19113 | |
| 0.19 | 0.085 | 0.19 | Clk dual-specificity kinase inhibitor | |||
| 0.128 | 0.023 | 0.203 | CC chemokine receptor antagonist | 0.203 0.011 CID_19113 | CID_19113 | |
| 0.155 | 0.051 | 0.155 | NADPH oxidase inhibitor | 0.119 0.084 CID_19113 | ||
| 0.153 | 0.05 | 0.153 | MAP kinase kinase inhibitor | 0.132 0.063 CID_19113 | ||
| 0.149 | 0.05 | 0.152 | TRKA antagonist | 0.152 0.049 CID_19113 | CID_19113 | |
| 0.121 | 0.025 | 0.19 | Raf kinase inhibitor | 0.19 0.014 CID_19113 | CID_19113 | |
| 0.107 | 0.013 | 0.111 | 5 Hydroxytryptamine 3 agonist | 0.111 0.011 CID_19113 | CID_19113 | |
| 0.117 | 0.025 | 0.117 | Rho-associated kinase II inhibitor | 0.117 0.026 CID_19113 | ||
| 0.104 | 0.012 | 0.104 | Melanin-concentrating hormone receptor 1 antagonist | 0.062 0.028 CID_19113 | ||
| 0.203 | 0.113 | 0.203 | MAP kinase kinase 3 inhibitor | 0.2 0.123 CID_19113 | ||
| 0.119 | 0.029 | 0.119 | NADH dehydrogenase inhibitor | 0.107 0.037 CID_19113 | ||
| 0.15 | 0.061 | 0.151 | Sphingosine 1-phosphate receptor 5 antagonist | 0.151 0.06 CID_19113 | CID_19113 | |
| 0.094 | 0.006 | 0.094 | Acetyl-CoA transferase 2 inhibitor | |||
| 0.099 | 0.013 | 0.099 | I kappa B kinase 2 inhibitor | 0.099 0.013 CID_19113 | ||
| 0.101 | 0.015 | 0.101 | Neuropeptide Y5 antagonist | |||
| 0.119 | 0.033 | 0.119 | Epidermal growth factor antagonist | 0.097 0.047 CID_19113 | ||
| 0.124 | 0.039 | 0.128 | Potassium channel (Ca-activated) activator | 0.128 0.036 CID_19113 | CID_19113 | |
| 0.104 | 0.019 | 0.104 | Sphingosine 1-phosphate receptor antagonist | 0.083 0.04 CID_19113 | ||
| 0.13 | 0.046 | 0.13 | Granulocyte macrophage colony stimulating factor antagonist | 0.091 0.083 CID_19113 | ||
| 0.108 | 0.024 | 0.108 | Dopamine agonist | |||
| 0.116 | 0.032 | 0.116 | ErbB-4 antagonist | 0.091 0.045 CID_19113 | ||
| 0.12 | 0.036 | 0.12 | 5 Hydroxytryptamine 2C antagonist | 0.089 0.053 CID_19113 | ||
| 0.15 | 0.069 | 0.164 | Growth factor antagonist | 0.164 0.061 CID_19113 | CID_19113 | |
| 0.134 | 0.054 | 0.134 | Aurora-B kinase inhibitor | 0.123 0.062 CID_19113 | ||
| 0.091 | 0.011 | 0.175 | CC chemokine 3 receptor antagonist | 0.175 0.005 CID_19113 | CID_19113 | |
| 0.087 | 0.007 | 0.087 | CXC chemokine 1 receptor antagonist | 0.065 0.016 CID_19113 | ||
| 0.11 | 0.03 | 0.113 | Glutamate release inhibitor | 0.113 0.027 CID_19113 | CID_19113 | |
| 0.111 | 0.034 | 0.118 | Platelet growth factor antagonist | 0.118 0.03 CID_19113 | CID_19113 | |
| 0.125 | 0.048 | 0.125 | MAP kinase kinase kinase inhibitor | 0.109 0.059 CID_19113 | ||
| 0.106 | 0.033 | 0.106 | ErbB-2 antagonist | 0.07 0.06 CID_19113 | ||
| 0.1 | 0.027 | 0.1 | GABA aminotransferase inhibitor | 0.092 0.033 CID_19113 | ||
| 0.149 | 0.077 | 0.149 | CF transmembrane conductance regulator agonist | 0.129 0.12 CID_19113 | ||
| 0.114 | 0.043 | 0.114 | HIV-1 integrase (Overall Integration) inhibitor | 0.105 0.05 CID_19113 | ||
| 0.111 | 0.04 | 0.111 | NMDA receptor antagonist | 0.104 0.045 CID_19113 | ||
| 0.135 | 0.065 | 0.145 | Alpha-N-acetylglucosaminidase inhibitor | 0.145 0.058 CID_19113 | CID_19113 | |
| 0.073 | 0.004 | 0.073 | Protein kinase (CK2) beta inhibitor | 0.038 0.014 CID_19113 | ||
| 0.148 | 0.081 | 0.148 | Hexokinase inhibitor | 0.134 0.098 CID_19113 | ||
| 0.07 | 0.004 | 0.07 | CXC chemokine 2 receptor antagonist | 0.045 0.007 CID_19113 | ||
| 0.099 | 0.034 | 0.148 | mTOR complex 2 inhibitor | 0.148 0.009 CID_19113 | CID_19113 | |
| 0.112 | 0.048 | 0.112 | Insulin receptor antagonist | |||
| 0.076 | 0.013 | 0.076 | Dihydroorotate oxidase inhibitor | 0.075 0.014 CID_19113 | ||
| 0.068 | 0.005 | 0.068 | NMDA receptor glycine site antagonist | 0.054 0.005 CID_19113 | ||
| 0.114 | 0.052 | 0.114 | Beta glucuronidase inhibitor | |||
| 0.108 | 0.045 | 0.128 | Glutamate (mGluR7) agonist | 0.128 0.023 CID_19113 | CID_19113 | |
| 0.085 | 0.023 | 0.085 | Carbonic anhydrase I inhibitor | 0.061 0.034 CID_19113 | ||
| 0.135 | 0.075 | 0.135 | Cytokine production inhibitor | 0.124 0.085 CID_19113 | ||
| 0.078 | 0.018 | 0.08 | AMPA receptor antagonist | 0.08 0.017 CID_19113 | CID_19113 | |
| 0.111 | 0.05 | 0.111 | UDP-glucose 4-epimerase inhibitor | 0.104 0.056 CID_19113 | ||
| 0.12 | 0.06 | 0.12 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.075 | 0.016 | 0.075 | Prolactin release inhibitor | |||
| 0.066 | 0.007 | 0.115 | Potassium channel Kv1.1 blocker | 0.115 0.004 CID_19113 | CID_19113 | |
| 0.123 | 0.066 | 0.123 | MAP kinase 12 inhibitor | 0.123 0.066 CID_19113 | ||
| 0.077 | 0.02 | 0.089 | CC chemokine 2 receptor antagonist | 0.089 0.016 CID_19113 | CID_19113 | |
| 0.08 | 0.024 | 0.08 | EphB4 antagonist | 0.071 0.028 CID_19113 | ||
| 0.094 | 0.038 | 0.134 | Vanilloid antagonist | 0.134 0.024 CID_19113 | CID_19113 | |
| 0.116 | 0.061 | 0.164 | CDK3/cyclin E inhibitor | 0.164 0.019 CID_19113 | CID_19113 | |
| 0.101 | 0.046 | 0.101 | Bile acid receptor antagonist | 0.089 0.077 CID_19113 | ||
| 0.101 | 0.046 | 0.171 | Potassium channel activator | 0.171 0.014 CID_19113 | CID_19113 | |
| 0.147 | 0.092 | 0.147 | Arachidonic acid antagonist | 0.127 0.116 CID_19113 | ||
| 0.095 | 0.041 | 0.095 | Acetylcholine nicotinic agonist | 0.087 0.048 CID_19113 | ||
| 0.067 | 0.014 | 0.079 | Potassium channel (Inward rectifier) activator | 0.079 0.008 CID_19113 | CID_19113 | |
| 0.078 | 0.026 | 0.078 | Purinergic P2X1 antagonist | 0.071 0.031 CID_19113 | ||
| 0.094 | 0.041 | 0.108 | Histamine H2 receptor antagonist | 0.108 0.028 CID_19113 | CID_19113 | |
| 0.163 | 0.111 | 0.171 | Focal adhesion kinase 2 inhibitor | 0.171 0.098 CID_19113 | CID_19113 | |
| 0.089 | 0.038 | 0.089 | Ca(v)3.1 blocker | |||
| 0.064 | 0.013 | 0.076 | Potassium channel (ATP-sensitive) activator | 0.076 0.008 CID_19113 | CID_19113 | |
| 0.075 | 0.027 | 0.075 | 5 Hydroxytryptamine 5A antagonist | 0.061 0.043 CID_19113 | ||
| 0.083 | 0.035 | 0.175 | Vanilloid 1 antagonist | 0.175 0.012 CID_19113 | CID_19113 | |
| 0.077 | 0.029 | 0.101 | Cannabinoid CB1 receptor antagonist | 0.101 0.016 CID_19113 | CID_19113 | |
| 0.068 | 0.02 | 0.068 | Sphingosine 1-phosphate receptor 1 antagonist | 0.052 0.049 CID_19113 | ||
| 0.056 | 0.008 | 0.071 | Integrin alpha2 antagonist | 0.071 0.005 CID_19113 | CID_19113 | |
| 0.075 | 0.027 | 0.075 | Carbonic anhydrase II inhibitor | 0.054 0.04 CID_19113 | ||
| 0.106 | 0.059 | 0.106 | Adenylate kinase inhibitor | 0.094 0.078 CID_19113 | ||
| 0.082 | 0.035 | 0.082 | CXC chemokine receptor antagonist | |||
| 0.084 | 0.038 | 0.129 | Adenosine A3 receptor antagonist | 0.129 0.015 CID_19113 | CID_19113 | |
| 0.056 | 0.011 | 0.056 | Diamine oxidase inhibitor | |||
| 0.105 | 0.06 | 0.105 | Carbonic anhydrase XV inhibitor | 0.095 0.074 CID_19113 | ||
| 0.051 | 0.006 | 0.07 | Cyclophilin A inhibitor | 0.07 0.004 CID_19113 | CID_19113 | |
| 0.062 | 0.017 | 0.062 | CC chemokine receptor 2B antagonist | 0.058 0.02 CID_19113 | ||
| 0.087 | 0.044 | 0.087 | Catalase inhibitor | 0.067 0.057 CID_19113 | ||
| 0.068 | 0.026 | 0.207 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.207 0.006 CID_19113 | CID_19113 | |
| 0.081 | 0.038 | 0.081 | Prostaglandin-E synthase inhibitor | 0.063 0.058 CID_19113 | ||
| 0.07 | 0.028 | 0.07 | Cyclin D1 inhibitor | 0.06 0.042 CID_19113 | ||
| 0.057 | 0.016 | 0.057 | Benzodiazepine antagonist | 0.051 0.024 CID_19113 | ||
| 0.216 | 0.175 | 0.361 | Calpain 2 inhibitor | 0.361 0.081 CID_19113 | CID_19113 | |
| 0.077 | 0.036 | 0.077 | Carbonic anhydrase inhibitor | |||
| 0.046 | 0.007 | 0.085 | Epoxide hydrolase 2 inhibitor | 0.085 0.004 CID_19113 | CID_19113 | |
| 0.045 | 0.006 | 0.047 | Calcium-sensing receptor agonist | 0.047 0.005 CID_19113 | CID_19113 | |
| 0.044 | 0.005 | 0.044 | Protease (Human cytomegalovirus) inhibitor | 0.035 0.006 CID_19113 | ||
| 0.061 | 0.022 | 0.066 | Heparanase inhibitor | 0.066 0.015 CID_19113 | CID_19113 | |
| 0.135 | 0.096 | 0.171 | GABA C receptor rho-2 antagonist | 0.171 0.05 CID_19113 | CID_19113 | |
| 0.05 | 0.011 | 0.062 | AMPA 1 receptor antagonist | 0.062 0.009 CID_19113 | CID_19113 | |
| 0.067 | 0.029 | 0.067 | 5 Hydroxytryptamine 5 antagonist | 0.056 0.044 CID_19113 | ||
| 0.104 | 0.066 | 0.104 | AMP-activated protein kinase stimulant | 0.103 0.067 CID_19113 | ||
| 0.082 | 0.044 | 0.082 | Rho-associated kinase I inhibitor | 0.082 0.044 CID_19113 | ||
| 0.042 | 0.005 | 0.054 | Integrin alpha2beta1 antagonist | 0.054 0.004 CID_19113 | CID_19113 | |
| 0.055 | 0.018 | 0.055 | Purinergic P2X4 antagonist | 0.052 0.022 CID_19113 | ||
| 0.194 | 0.158 | 0.215 | 12-Lipoxygenase inhibitor | 0.215 0.135 CID_19113 | CID_19113 | |
| 0.163 | 0.127 | 0.163 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.067 | 0.031 | 0.078 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.078 0.021 CID_19113 | CID_19113 | |
| 0.095 | 0.059 | 0.095 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.095 0.059 CID_19113 | ||
| 0.05 | 0.014 | 0.081 | Inosine monophosphate dehydrogenase inhibitor | 0.081 0.007 CID_19113 | CID_19113 | |
| 0.07 | 0.034 | 0.091 | Beta 3 adrenoreceptor antagonist | 0.091 0.017 CID_19113 | CID_19113 | |
| 0.068 | 0.033 | 0.115 | Alpha 2 adrenoreceptor agonist | 0.115 0.011 CID_19113 | CID_19113 | |
| 0.055 | 0.021 | 0.058 | CC chemokine 4 receptor antagonist | 0.058 0.018 CID_19113 | CID_19113 | |
| 0.056 | 0.021 | 0.102 | Cholecystokinin antagonist | 0.102 0.008 CID_19113 | CID_19113 | |
| 0.046 | 0.012 | 0.046 | Potassium channel small-conductance Ca-activated activator | 0.037 0.017 CID_19113 | ||
| 0.076 | 0.042 | 0.076 | p38 MAP kinase inhibitor | 0.057 0.054 CID_19113 | ||
| 0.095 | 0.061 | 0.095 | Prolactin inhibitor | |||
| 0.095 | 0.063 | 0.095 | Lanosterol 14 alpha demethylase inhibitor | 0.09 0.073 CID_19113 | ||
| 0.04 | 0.007 | 0.04 | 5 Hydroxytryptamine 1F agonist | |||
| 0.121 | 0.089 | 0.121 | Ribosomal protein S6 kinase inhibitor | |||
| 0.079 | 0.048 | 0.125 | MAP kinase 14 inhibitor | 0.125 0.026 CID_19113 | CID_19113 | |
| 0.073 | 0.043 | 0.087 | Carbonic anhydrase VA inhibitor | 0.087 0.032 CID_19113 | CID_19113 | |
| 0.082 | 0.051 | 0.13 | Cell adhesion molecule inhibitor | 0.13 0.02 CID_19113 | CID_19113 | |
| 0.041 | 0.011 | 0.041 | Adenosine uptake inhibitor | 0.035 0.024 CID_19113 | ||
| 0.042 | 0.013 | 0.049 | AMPA 3 receptor antagonist | 0.049 0.009 CID_19113 | CID_19113 | |
| 0.13 | 0.1 | 0.13 | Pregnane X receptor agonist | |||
| 0.067 | 0.038 | 0.083 | Adrenaline uptake inhibitor | 0.083 0.025 CID_19113 | CID_19113 | |
| 0.04 | 0.011 | 0.053 | Epoxide hydrolase 1 inhibitor | 0.053 0.005 CID_19113 | CID_19113 | |
| 0.1 | 0.072 | 0.1 | 5 Hydroxytryptamine 2 antagonist | |||
| 0.056 | 0.028 | 0.056 | Proto-oncogene tyrosine-protein kinase Met inhibitor | |||
| 0.031 | 0.003 | 0.033 | Thromboxane A2 agonist | 0.033 0.003 CID_19113 | CID_19113 | |
| 0.092 | 0.064 | 0.116 | Potassium channel (Voltage-sensitive) activator | 0.116 0.035 CID_19113 | CID_19113 | |
| 0.043 | 0.017 | 0.043 | CF transmembrane conductance regulator antagonist | 0.039 0.028 CID_19113 | ||
| 0.057 | 0.031 | 0.068 | NMDA 2A receptor antagonist | 0.068 0.025 CID_19113 | CID_19113 | |
| 0.157 | 0.132 | 0.157 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | |||
| 0.087 | 0.062 | 0.091 | Falcipain 2 inhibitor | 0.091 0.059 CID_19113 | CID_19113 | |
| 0.17 | 0.146 | 0.284 | DNA damaging | 0.284 0.064 CID_19113 | CID_19113 | |
| 0.088 | 0.065 | 0.092 | Falcipain inhibitor | 0.092 0.061 CID_19113 | CID_19113 | |
| 0.075 | 0.051 | 0.075 | Rho-associated kinase inhibitor | 0.071 0.054 CID_19113 | ||
| 0.112 | 0.089 | 0.112 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.045 | 0.022 | 0.046 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.046 0.02 CID_19113 | CID_19113 | |
| 0.1 | 0.077 | 0.1 | Chelator | |||
| 0.06 | 0.037 | 0.06 | Calcium channel T-type blocker | |||
| 0.034 | 0.011 | 0.035 | MAP3K8 inhibitor | 0.035 0.011 CID_19113 | CID_19113 | |
| 0.1 | 0.079 | 0.118 | Platelet activating factor antagonist | 0.118 0.064 CID_19113 | CID_19113 | |
| 0.164 | 0.143 | 0.164 | Immunostimulant | |||
| 0.132 | 0.111 | 0.132 | Ca2+-transporting ATPase inhibitor | 0.129 0.126 CID_19113 | ||
| 0.065 | 0.044 | 0.069 | Aryl hydrocarbon receptor antagonist | 0.069 0.039 CID_19113 | CID_19113 | |
| 0.116 | 0.095 | 0.116 | Protein kinase (CK1) inhibitor | |||
| 0.073 | 0.053 | 0.073 | S-adenosyl-L-methionine decarboxylase inhibitor | |||
| 0.073 | 0.055 | 0.079 | Vanilloid 4 agonist | 0.079 0.043 CID_19113 | CID_19113 | |
| 0.069 | 0.051 | 0.09 | Cannabinoid receptor antagonist | 0.09 0.033 CID_19113 | CID_19113 | |
| 0.082 | 0.064 | 0.082 | Insulin growth factor antagonist | |||
| 0.067 | 0.048 | 0.067 | MDM2 inhibitor | 0.065 0.055 CID_19113 | ||
| 0.035 | 0.017 | 0.035 | Glucagon receptor antagonist | 0.026 0.024 CID_19113 | ||
| 0.029 | 0.012 | 0.029 | Complement factor 1r inhibitor | 0.029 0.012 CID_19113 | ||
| 0.085 | 0.068 | 0.085 | Triose-phosphate isomerase inhibitor | 0.084 0.068 CID_19113 | ||
| 0.065 | 0.048 | 0.081 | Carbonic anhydrase V inhibitor | 0.081 0.035 CID_19113 | CID_19113 | |
| 0.084 | 0.068 | 0.088 | Bromodomain-containing protein 2 inhibitor | 0.088 0.059 CID_19113 | CID_19113 | |
| 0.133 | 0.117 | 0.172 | TRKC antagonist | 0.172 0.084 CID_19113 | CID_19113 | |
| 0.149 | 0.134 | 0.172 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.172 0.103 CID_19113 | CID_19113 | |
| 0.038 | 0.023 | 0.077 | Kainate receptor 2 antagonist | 0.077 0.007 CID_19113 | CID_19113 | |
| 0.078 | 0.063 | 0.078 | Insulin like growth factor 1 antagonist | |||
| 0.224 | 0.209 | 0.252 | Analgesic | 0.252 0.181 CID_19113 | CID_19113 | |
| 0.118 | 0.104 | 0.118 | Mannose-6-phosphate isomerase inhibitor | |||
| 0.131 | 0.117 | 0.131 | Heat shock protein 70 antagonist | |||
| 0.08 | 0.066 | 0.08 | Myeloperoxidase inhibitor | |||
| 0.083 | 0.07 | 0.083 | Pim-3 kinase inhibitor | |||
| 0.043 | 0.031 | 0.043 | Histamine H1 receptor agonist | 0.042 0.035 CID_19113 | ||
| 0.123 | 0.111 | 0.123 | Sigma receptor agonist | |||
| 0.139 | 0.127 | 0.148 | Psychostimulant | 0.148 0.118 CID_19113 | CID_19113 | |
| 0.03 | 0.018 | 0.037 | Thrombin receptor antagonist | 0.037 0.013 CID_19113 | CID_19113 | |
| 0.054 | 0.044 | 0.063 | Immunoglobulin Fc receptor antagonist | 0.063 0.019 CID_19113 | CID_19113 | |
| 0.165 | 0.155 | 0.185 | Calpain inhibitor | 0.185 0.128 CID_19113 | CID_19113 | |
| 0.1 | 0.09 | 0.162 | Cell adhesion inhibitor | 0.162 0.04 CID_19113 | CID_19113 | |
| 0.04 | 0.03 | 0.04 | Thymidine kinase inhibitor | 0.037 0.035 CID_19113 | ||
| 0.221 | 0.212 | 0.221 | DNA directed DNA polymerase inhibitor | |||
| 0.023 | 0.013 | 0.046 | Kainate receptor 5 antagonist | 0.046 0.006 CID_19113 | CID_19113 | |
| 0.022 | 0.012 | 0.022 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.02 0.018 CID_19113 | ||
| 0.034 | 0.025 | 0.034 | Benzodiazepine receptor peripheral-type antagonist | |||
| 0.038 | 0.029 | 0.038 | Dopamine D3 agonist | |||
| 0.039 | 0.031 | 0.039 | Neurokinin 2 antagonist | |||
| 0.121 | 0.113 | 0.121 | CC chemokine 6 receptor antagonist | |||
| 0.092 | 0.085 | 0.112 | Tyrosine-protein kinase receptor FLT3 inhibitor | 0.112 0.073 CID_19113 | CID_19113 | |
| 0.055 | 0.048 | 0.055 | Carbamoyl phosphate synthetase inhibitor | 0.053 0.051 CID_19113 | ||
| 0.029 | 0.022 | 0.029 | Acetylcholine M4 receptor agonist | |||
| 0.029 | 0.022 | 0.045 | Cholecystokinin B antagonist | 0.045 0.012 CID_19113 | CID_19113 | |
| 0.053 | 0.046 | 0.053 | Dopamine uptake inhibitor | 0.05 0.049 CID_19113 | ||
| 0.181 | 0.174 | 0.183 | Tyrosine 3 hydroxylase inhibitor | 0.183 0.169 CID_19113 | CID_19113 | |
| 0.074 | 0.067 | 0.074 | Glycine receptor antagonist | |||
| 0.021 | 0.015 | 0.037 | Kainate receptor 1 antagonist | 0.037 0.008 CID_19113 | CID_19113 | |
| 0.016 | 0.01 | 0.016 | Purinergic P2Y1 antagonist | 0.015 0.012 CID_19113 | ||
| 0.135 | 0.129 | 0.156 | 3C-like protease (Human coronavirus) inhibitor | 0.156 0.091 CID_19113 | CID_19113 | |
| 0.041 | 0.035 | 0.055 | Purinergic P2Y antagonist | 0.055 0.022 CID_19113 | CID_19113 | |
| 0.045 | 0.039 | 0.054 | Cholesterol esterase inhibitor | 0.054 0.024 CID_19113 | CID_19113 | |
| 0.034 | 0.029 | 0.047 | Bombesin 1 receptor antagonist | 0.047 0.015 CID_19113 | CID_19113 | |
| 0.088 | 0.083 | 0.088 | Falcipain 3 inhibitor | |||
| 0.084 | 0.08 | 0.084 | Phosphodiesterase 7B inhibitor | |||
| 0.084 | 0.08 | 0.084 | Aurora-A kinase inhibitor | |||
| 0.066 | 0.062 | 0.072 | Phospholipase D inhibitor | 0.072 0.048 CID_19113 | CID_19113 | |
| 0.008 | 0.004 | 0.008 | DNA topoisomerase III inhibitor | 0.008 0.004 CID_19113 | ||
| 0.113 | 0.109 | 0.113 | Cytidine deaminase inhibitor | |||
| 0.063 | 0.06 | 0.084 | Amidase inhibitor | 0.084 0.034 CID_19113 | CID_19113 | |
| 0.033 | 0.029 | 0.08 | Cholecystokinin A antagonist | 0.08 0.012 CID_19113 | CID_19113 | |
| 0.061 | 0.058 | 0.101 | Potassium channel (ATP-sensitive) blocker | 0.101 0.015 CID_19113 | CID_19113 | |
| 0.062 | 0.059 | 0.065 | Histidine decarboxylase inhibitor | 0.065 0.056 CID_19113 | CID_19113 | |
| 0.029 | 0.026 | 0.039 | LIM domain kinase 2 inhibitor | 0.039 0.01 CID_19113 | CID_19113 | |
| 0.116 | 0.114 | 0.134 | Acetylcholine M1 receptor antagonist | 0.134 0.091 CID_19113 | CID_19113 | |
| 0.035 | 0.033 | 0.035 | Substance P antagonist | |||
| 0.048 | 0.045 | 0.056 | Phosphodiesterase 7A inhibitor | 0.056 0.027 CID_19113 | CID_19113 | |
| 0.061 | 0.058 | 0.064 | Potassium channel large-conductance Ca-activated activator | 0.064 0.052 CID_19113 | CID_19113 | |
| 0.137 | 0.135 | 0.151 | I kappa B kinase epsilon inhibitor | 0.151 0.119 CID_19113 | CID_19113 | |
| 0.102 | 0.1 | 0.167 | Protein-tyrosine kinase Lyn inhibitor | 0.167 0.058 CID_19113 | CID_19113 | |
| 0.031 | 0.029 | 0.031 | Carnitine palmitoyltransferase inhibitor | |||
| 0.01 | 0.008 | 0.01 | Thromboxane agonist | 0.01 0.009 CID_19113 | ||
| 0.025 | 0.024 | 0.025 | Thymidine kinase (Herpes simplex virus 1) inhibitor | |||
| 0.19 | 0.188 | 0.221 | Vasodilator, peripheral | 0.221 0.153 CID_19113 | CID_19113 | |
| 0.063 | 0.062 | 0.063 | Macrophage colony-stimulating factor 1 receptor antagonist | |||
| 0.052 | 0.051 | 0.052 | Botulinum neurotoxin type A inhibitor | |||
| 0.04 | 0.039 | 0.075 | Fructose-1,6-bisphosphatase inhibitor | 0.075 0.01 CID_19113 | CID_19113 | |
| 0.034 | 0.034 | 0.056 | DNA gyrase subunit B inhibitor | 0.056 0.01 CID_19113 | CID_19113 | |
| 0.085 | 0.086 | 0.108 | Gastric antisecretory | 0.108 0.055 CID_19113 | CID_19113 | |
| 0.054 | 0.055 | 0.075 | Purinergic P2 antagonist | 0.075 0.036 CID_19113 | CID_19113 | |
| 0.016 | 0.017 | 0.034 | Alpha 2c adrenoreceptor agonist | 0.034 0.004 CID_19113 | CID_19113 | |
| 0.101 | 0.105 | 0.107 | Cathepsin H inhibitor | 0.107 0.094 CID_19113 | CID_19113 | |
| 0.049 | 0.052 | 0.079 | Raf kinase B inhibitor | 0.079 0.03 CID_19113 | CID_19113 | |
| 0.037 | 0.04 | 0.065 | NMDA receptor subunit 3B antagonist | 0.065 0.017 CID_19113 | CID_19113 | |
| 0.035 | 0.04 | 0.042 | Glucagon-like peptide 1 receptor antagonist | 0.042 0.023 CID_19113 | CID_19113 | |
| 0.161 | 0.167 | 0.191 | Peptidyltransferase inhibitor | 0.191 0.111 CID_19113 | CID_19113 | |
| 0.042 | 0.049 | 0.061 | mTOR inhibitor | 0.061 0.028 CID_19113 | CID_19113 | |
| 0.033 | 0.042 | 0.045 | Carbonic anhydrase IV inhibitor | 0.045 0.028 CID_19113 | CID_19113 | |
| 0.019 | 0.028 | 0.03 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.03 0.008 CID_19113 | CID_19113 | |
| 0.089 | 0.098 | 0.101 | GABA C receptor antagonist | 0.101 0.076 CID_19113 | CID_19113 | |
| 0.029 | 0.038 | 0.041 | Potassium channel KCNQ activator | 0.041 0.022 CID_19113 | CID_19113 | |
| 0.029 | 0.038 | 0.041 | Delayed rectifier potassium channel activator | 0.041 0.022 CID_19113 | CID_19113 | |
| 0.027 | 0.037 | 0.031 | GHS receptor antagonist | 0.031 0.025 CID_19113 | CID_19113 | |
| 0.012 | 0.022 | 0.018 | Alpha 2a adrenoreceptor agonist | 0.018 0.011 CID_19113 | CID_19113 | |
| 0.017 | 0.027 | 0.049 | CC chemokine 1 receptor antagonist | 0.049 0.007 CID_19113 | CID_19113 | |
| 0.238 | 0.249 | 0.295 | MAP kinase 1 inhibitor | 0.295 0.186 CID_19113 | CID_19113 | |
| 0.037 | 0.05 | 0.043 | Glutamate (mGluR4) antagonist | 0.043 0.031 CID_19113 | CID_19113 | |
| 0.043 | 0.058 | 0.072 | Beta 1 adrenoreceptor antagonist | 0.072 0.024 CID_19113 | CID_19113 | |
| 0.06 | 0.075 | 0.071 | Glutamate dehydrogenase inhibitor | 0.071 0.055 CID_19113 | CID_19113 | |
| 0.026 | 0.042 | 0.048 | NMDA receptor subunit 3A antagonist | 0.048 0.021 CID_19113 | CID_19113 | |
| 0.021 | 0.041 | 0.028 | Peptide deformylase inhibitor | 0.028 0.023 CID_19113 | CID_19113 | |
| 0.089 | 0.112 | 0.1 | Nav1.3 sodium channel blocker | 0.1 0.098 CID_19113 | CID_19113 | |
| 0.034 | 0.057 | 0.185 | Phosphatidylinositol 3-kinase alpha inhibitor | 0.185 0.008 CID_19113 | CID_19113 | |
| 0.153 | 0.177 | 0.206 | 5 Hydroxytryptamine release stimulant | 0.206 0.117 CID_19113 | CID_19113 | |
| 0.013 | 0.038 | 0.021 | Alpha 2b adrenoreceptor agonist | 0.021 0.009 CID_19113 | CID_19113 | |
| 0.163 | 0.19 | 0.199 | Transcription factor STAT3 inhibitor | 0.199 0.135 CID_19113 | CID_19113 | |
| 0.135 | 0.163 | 0.165 | Neurotrophic factor enhancer | 0.165 0.117 CID_19113 | CID_19113 | |
| 0.015 | 0.044 | 0.027 | AMPA 2 receptor antagonist | 0.027 0.023 CID_19113 | CID_19113 | |
| 0.073 | 0.103 | 0.086 | Polo-like kinase-1 inhibitor | 0.086 0.071 CID_19113 | CID_19113 | |
| 0.012 | 0.043 | 0.031 | Bradykinin B2 receptor antagonist | 0.031 0.022 CID_19113 | CID_19113 | |
| 0.034 | 0.065 | 0.058 | Beta 2 adrenoreceptor antagonist | 0.058 0.026 CID_19113 | CID_19113 | |
| 0.045 | 0.079 | 0.066 | Fibroblast growth factor 2 antagonist | 0.066 0.044 CID_19113 | CID_19113 | |
| 0.055 | 0.09 | 0.092 | Fibroblast growth factor 3 antagonist | 0.092 0.038 CID_19113 | CID_19113 | |
| 0.082 | 0.116 | 0.13 | Alkylator | 0.13 0.06 CID_19113 | CID_19113 | |
| 0.075 | 0.111 | 0.099 | GABA C receptor rho-1 antagonist | 0.099 0.063 CID_19113 | CID_19113 | |
| 0.111 | 0.148 | 0.123 | Adenylate cyclase stimulant | 0.123 0.118 CID_19113 | CID_19113 | |
| 0.063 | 0.1 | 0.092 | Fibroblast growth factor 1 antagonist | 0.092 0.064 CID_19113 | CID_19113 | |
| 0.035 | 0.077 | 0.05 | Nicotinic alpha7 receptor agonist | 0.05 0.042 CID_19113 | CID_19113 | |
| 0.027 | 0.07 | 0.048 | Ribonucleotide reductase inhibitor | 0.048 0.044 CID_19113 | CID_19113 | |
| 0.161 | 0.21 | 0.189 | Transcription factor STAT inhibitor | 0.189 0.154 CID_19113 | CID_19113 | |
| 0.081 | 0.132 | 0.114 | Lck kinase inhibitor | 0.114 0.09 CID_19113 | CID_19113 | |
| 0.07 | 0.122 | 0.095 | Anabolic | 0.095 0.07 CID_19113 | CID_19113 | |
| 0.031 | 0.087 | 0.05 | Nicotinic neuronal receptor agonist | 0.05 0.046 CID_19113 | CID_19113 | |
| 0.043 | 0.099 | 0.065 | Beta adrenoreceptor antagonist | 0.065 0.047 CID_19113 | CID_19113 | |
| 0.04 | 0.101 | 0.076 | Alpha adrenoreceptor agonist | 0.076 0.041 CID_19113 | CID_19113 | |
| 0.027 | 0.088 | 0.065 | Tyk2 inhibitor | 0.065 0.044 CID_19113 | CID_19113 | |
| 0.123 | 0.185 | 0.142 | Neurotensin receptor agonist | 0.142 0.124 CID_19113 | CID_19113 | |
| 0.035 | 0.099 | 0.133 | Phosphatidylinositol kinase inhibitor | 0.133 0.014 CID_19113 | CID_19113 | |
| 0.05 | 0.116 | 0.098 | Platelet activating factor beta antagonist | 0.098 0.064 CID_19113 | CID_19113 | |
| 0.044 | 0.111 | 0.07 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.07 0.06 CID_19113 | CID_19113 | |
| 0.084 | 0.153 | 0.121 | Interleukin 4 antagonist | 0.121 0.084 CID_19113 | CID_19113 | |
| 0.074 | 0.143 | 0.105 | Cyclin-dependent kinase 7 inhibitor | 0.105 0.096 CID_19113 | CID_19113 | |
| 0.095 | 0.167 | 0.114 | Vanilloid 1 agonist | 0.114 0.103 CID_19113 | CID_19113 | |
| 0.021 | 0.095 | 0.031 | Glutamate (mGluR3) agonist | 0.031 0.026 CID_19113 | CID_19113 | |
| 0.037 | 0.117 | 0.064 | Check point kinase 1 inhibitor | 0.064 0.052 CID_19113 | CID_19113 | |
| 0.048 | 0.128 | 0.085 | Adrenaline agonist | 0.085 0.051 CID_19113 | CID_19113 | |
| 0.044 | 0.129 | 0.084 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.084 0.048 CID_19113 | CID_19113 | |
| 0.094 | 0.183 | 0.126 | Thiol protease inhibitor | 0.126 0.103 CID_19113 | CID_19113 | |
| 0.037 | 0.127 | 0.119 | DNA gyrase inhibitor | 0.119 0.013 CID_19113 | CID_19113 | |
| 0.106 | 0.203 | 0.181 | Death-associated protein kinase 3 inhibitor | 0.181 0.087 CID_19113 | CID_19113 | |
| 0.118 | 0.232 | 0.194 | Histone acetyltransferase inhibitor | 0.194 0.079 CID_19113 | CID_19113 | |
| 0.019 | 0.134 | 0.03 | DNA topoisomerase IV inhibitor | 0.03 0.02 CID_19113 | CID_19113 | |
| 0.061 | 0.192 | 0.099 | Microtubule formation inhibitor | 0.099 0.092 CID_19113 | CID_19113 | |
| 0.058 | 0.19 | 0.106 | Interleukin 1b antagonist | 0.106 0.074 CID_19113 | CID_19113 | |
| 0.023 | 0.174 | 0.039 | VCAM antagonist | 0.039 0.03 CID_19113 | CID_19113 | |
| 0.023 | 0.174 | 0.039 | VCAM-1 antagonist | 0.039 0.03 CID_19113 | CID_19113 | |
| 0.02 | 0.176 | 0.044 | Baculoviral IAP repeat-containing protein inhibitor | 0.044 0.039 CID_19113 | CID_19113 | |
| 0.078 | 0.249 | 0.147 | Anticonvulsant | 0.147 0.133 CID_19113 | CID_19113 | |
| 0.004 | 0.22 | 0.019 | Growth hormone release promoting | 0.019 0.014 CID_19113 | CID_19113 | |
| 0.042 | 0.267 | 0.101 | Thioredoxin inhibitor | 0.101 0.047 CID_19113 | CID_19113 | |
| 0.006 | 0.254 | 0.034 | Growth hormone releasing factor agonist | 0.034 0.022 CID_19113 | CID_19113 | |
| 0.032 | 0.469 | 0.091 | mTOR complex 1 inhibitor | 0.091 0.084 CID_19113 | CID_19113 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |